These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 23636219)

  • 81. [Health economics of inhibitor bypassing agents in haemophilia A-activated prothrombin complex concentrate (aPCC) and recombinant activated factor VIIa (rFVIIa)].
    Szmurło D; Deryło Ł; Ryś P; Władysiuk M
    Pol Merkur Lekarski; 2011 Mar; 30(177):202-7. PubMed ID: 21544998
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Prothrombin complex concentrate for non-vitamin K oral anticoagulant reversal: good enough for now?
    Makris M
    J Thromb Haemost; 2014 Sep; 12(9):1425-7. PubMed ID: 25039898
    [No Abstract]   [Full Text] [Related]  

  • 83. Incidence of thrombotic complications related to weight-based dosing of activated prothrombin complex concentrate (aPCC) for reversal of apixaban and rivaroxaban in obese patients.
    Whitaker C; McKinney A; Bollig R; Hieb N; Roberts RF; Rowe AS
    J Thromb Thrombolysis; 2022 May; 53(4):861-867. PubMed ID: 34787787
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey.
    Van Blerk M; Bailleul E; Chatelain B; Demulder A; Devreese K; Douxfils J; Jochmans K; Mullier F; Wijns W; Soumali MR; Coucke W; Vernelen K; Van de Walle P
    Thromb Haemost; 2015 Jan; 113(1):154-64. PubMed ID: 25231101
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate.
    Dinkelaar J; Patiwael S; Harenberg J; Leyte A; Brinkman HJ
    Clin Chem Lab Med; 2014 Nov; 52(11):1615-23. PubMed ID: 24902009
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Emergency reversal of pentasaccharide anticoagulants: a systematic review of the literature.
    Elmer J; Wittels KA
    Transfus Med; 2012 Apr; 22(2):108-15. PubMed ID: 22171588
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Thrombin generation in real life bleeding patients on oral anticoagulants reversed (or not) with (activated) prothrombin complex concentrate.
    Teissandier D; Moustafa F; Denaives A; Lebecque B; Blondonnet R; Pereira B; Monfoulet LE; Sinegre T; Schmidt J; Lebreton A
    Thromb Res; 2023 Mar; 223():184-193. PubMed ID: 36764085
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects.
    Skolnick BE; Mathews DR; Khutoryansky NM; Pusateri AE; Carr ME
    Blood; 2010 Aug; 116(5):693-701. PubMed ID: 20385794
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Recombinant activated factor VII and prothrombin complex concentrates have different effects on bleeding and arterial thrombosis in the haemodiluted rabbit.
    Le Saché F; Le Bonniec B; Gaussem P; Dizier B; Tagzirt M; Godier A; Emmerich J; Samama CM
    Br J Anaesth; 2012 Apr; 108(4):586-93. PubMed ID: 22258204
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Effects of increasing doses of activated recombinant factor VII on haemostatic parameters in swine.
    Pusateri AE; Ryan KL; Delgado AV; Martinez RS; Uscilowicz JM; Cortez DS; Martinowitz U
    Thromb Haemost; 2005 Feb; 93(2):275-83. PubMed ID: 15711743
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Factor (F)VIII/VIIa enhances global haemostatic function in the co-presence of bypassing agents and FVIII among patients with haemophilia A with inhibitor.
    Nogami K; Matsumoto T; Yada K; Ogiwara K; Furukawa S; Shida Y; Takeyama M; Shima M
    Br J Haematol; 2018 May; 181(4):528-536. PubMed ID: 29611182
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors?
    Rodriguez-Merchan EC; Hedner U; Heijnen L; Jimenez-Yuste V; Lee CA; Morfini M; Querol F; Roosendaal G; Santagostino E; Solimeno LP
    Haemophilia; 2008 Nov; 14 Suppl 6():68-81. PubMed ID: 19134036
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Discussion of "Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa".
    Van Dusen R
    Am J Surg; 2018 May; 215(5):780-781. PubMed ID: 29366484
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature.
    Caviglia H; Candela M; Galatro G; Neme D; Moretti N; Bianco RP
    Haemophilia; 2011 Nov; 17(6):910-9. PubMed ID: 21342367
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.
    Douxfils J; Mullier F; Loosen C; Chatelain C; Chatelain B; Dogné JM
    Thromb Res; 2012 Dec; 130(6):956-66. PubMed ID: 23006523
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Assays for measuring rivaroxaban: their suitability and limitations.
    Lindhoff-Last E; Samama MM; Ortel TL; Weitz JI; Spiro TE
    Ther Drug Monit; 2010 Dec; 32(6):673-9. PubMed ID: 20844464
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Correcting thrombin generation ex vivo using different haemostatic agents following cardiac surgery requiring the use of cardiopulmonary bypass.
    Percy CL; Hartmann R; Jones RM; Balachandran S; Mehta D; Dockal M; Scheiflinger F; O'Donnell VB; Hall JE; Collins PW
    Blood Coagul Fibrinolysis; 2015 Jun; 26(4):357-67. PubMed ID: 25928274
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Strategies for urgent reversal of target-specific oral anticoagulants.
    Davis EM; Uhlmeyer EM; Schmidt DP; Schardt GL
    Hosp Pract (1995); 2014 Dec; 42(5):108-25. PubMed ID: 25485923
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Heparin supplement counteracts the prohemostatic effect of prothrombin complex concentrate and factor IX concentrate: An in vitro evaluation.
    Brinkman HJ; Patiwael S; Tripathi S; Meijers JC
    Thromb Res; 2016 Mar; 139():102-10. PubMed ID: 26916304
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
    Laux V; Perzborn E; Kubitza D; Misselwitz F
    Semin Thromb Hemost; 2007 Jul; 33(5):515-23. PubMed ID: 17629849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.